Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Crosses Below 200 Day Moving Average of $6.98

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.98 and traded as low as $5.08. Aurinia Pharmaceuticals shares last traded at $5.20, with a volume of 1,441,524 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on AUPH shares. Jefferies Financial Group cut their price objective on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a "hold" rating on the stock in a research report on Friday, February 16th. Royal Bank of Canada reduced their price objective on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an "outperform" rating for the company in a research note on Friday, February 16th. Cantor Fitzgerald lowered their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. StockNews.com raised shares of Aurinia Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, May 3rd. Finally, HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, March 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.00.

Aurinia Pharmaceuticals Trading Up 2.1 %

The firm has a 50 day simple moving average of $5.10 and a 200 day simple moving average of $6.97. The firm has a market cap of $757.52 million, a P/E ratio of -12.35 and a beta of 1.36. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.05 and a current ratio of 5.60.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03). The business had revenue of $45.10 million during the quarter, compared to analysts' expectations of $45.00 million. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. The company's quarterly revenue was up 58.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.18) EPS. On average, equities research analysts predict that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Aurinia Pharmaceuticals by 15.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company's stock worth $196,000 after acquiring an additional 5,079 shares in the last quarter. Patten & Patten Inc. TN purchased a new position in Aurinia Pharmaceuticals in the 1st quarter worth $386,000. Vanguard Group Inc. lifted its stake in Aurinia Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company's stock worth $7,673,000 after purchasing an additional 21,119 shares during the last quarter. Jupiter Asset Management Ltd. boosted its position in Aurinia Pharmaceuticals by 21.3% during the first quarter. Jupiter Asset Management Ltd. now owns 247,052 shares of the biotechnology company's stock valued at $1,238,000 after buying an additional 43,366 shares during the period. Finally, ProShare Advisors LLC grew its stake in shares of Aurinia Pharmaceuticals by 9.1% during the first quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company's stock valued at $173,000 after buying an additional 2,873 shares during the last quarter. Institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.